Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4 Puritas >99.5% EE >99.5%

Description:

Nomen: Boc-3-Hydroxy-1-Adamantyl-D-Glycine

CAS: 361442-00-4

Puritas: >99.5% (GC) EE: >99.5%

Aspectus: Alba vel Off-White Crystalline pulveris

Medium API (CAS: 361442-04-8)

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum Boc-3-Hydroxy-1-Adamantyl-D-Glycine
Synonyma (2S)-2-((tert-Butoxycarbonyl) amino) -2-(3-Hydroxyadamantan-1-yl) acidum aceticum
CAS Number 361442-00-4
CATTUS Number RF-PI1989
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C17H27NO5
M. Pondus 325.40
Ferveret 497.3±20.0℃
Density 1.296
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Alba vel Off-White Crystalline pulveris
Aquae (KF) <0.50%
Damnum in Siccatio <1.00%
Residere in Ignition <0.50%
una immunditia <0.50%
Totalis immunditias <0.50%
EE >99.5%
Puritas >99.5%
Infrared Imaginis Conformat ut Structure
Test Standard Enterprise Standard
Consuetudinem Pharmaceutical intermedia

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

1

FAQ:

Applicatio:

Boc-3-Hydroxy-1-Adamantyl-D-Glycine (CAS: 361442-00-4) medium est API (CAS: 361442-04-8).API (CAS: 361442-04-8)est potens et selectivus convertibilis inhibitor dipeptidyli peptidasi-4, quod augetur ad tractationem diabetarum speciei 2 .Celeriter post administrationem oralis absorbetur et profile pharmacokineticae compatitur cum semel dosing cotidie.Est dipeptidylus peptidase-4 (DPP-4) inhibitor antidiabeticus ad curationem diabete speciei 2 .DPP-4 inhibitores sunt genus compositorum quae laborant actionem hormonum naturalium in corpore incretino vocato afficientes.Ituna cum victu et exercitatione adhibetur ad sanguinem saccharo emendandum in adultis temperantia cum diabete 2 speciei melliti.Non est tractandi genus 1 diabete.Itinterdum adhibetur medicamentum cum aliis diabete.Perventum est ab cooperatione AstraZeneca et Bristol-Myers Squibb Societatis et ad inhibitorem DPP-IV pertinet.

Epistulam tuam hic scribe et mitte nobis